Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FibroGen, AstraZeneca in anemia deal

FibroGen Inc. (San Francisco, Calif.) and AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered to develop and commercialize FibroGen's anemia

Read the full 177 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE